Private investment in pharmaceutical research can't replace the NIH. Both public investment and the private sector are needed ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

They are classified as glucagon-like peptide 1 (GLP-1) agonists and, in addition to diabetes treatment, also demonstrate other benefits including weight loss and protective heart-health effects.While ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...